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Abstract
Background: The consequences of strict COVID-19 mobility restrictions on motor/non-motor features in Parkinson’s
disease (PD) have not been systematically studied but worse mobility and quality of life have been reported. To
elucidate this question, 12 mild to moderate PD patients were assessed in March 2020 before and after two
months of isolation as part of a clinical study that had to be interrupted due to the pandemic and the
implementation of COVID19 mobility restrictions.
Methods: Twelve patients were systematically evaluated before and after the lockdown period as part of a larger
cohort that previously underwent thermal water rehabilitation. Clinical outcomes were the Body Mass index, the Mini-
Balance Evaluation Systems Test, the MDS-Unified Parkinson’s Disease Rating Scale part III, the 6 Minute Walking Test
and the New Freezing of Gait Questionnaire. Global cognition was evaluated with the Montreal Cognitive Assessment
scale. The impact of COVID-19 restrictions on quality of life and functional independence was evaluated with The
Parkinson’s disease Quality of life (PDQ-39), the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living
questionnaires (IADL) and the Parkinson’s disease cognitive functional rating scales (PD-CFRS).
Results: After two months of isolation the Mini-BESTest score worsened (p=0.005), and four patients reported one or
more falls during the lockdown. BMI increased (p=0.031) while the remaining clinical variables including quality of life
did not change.
Conclusion: We observed moderate worsening at Mini-BESTest, greater risk of falls and increased body weight as
consequence of prolonged immobility. We believe negative effects were partially softened since patients were in
contact with our multidisciplinary team during the lockdown and had previously received training to respond to the
needs of this emergency isolation. These findings highligh the importnace of patient-centered interventions in PD
management.
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Background
The COVID-19 pandemic has been declared as a global
emergency by the World Health Organization. Unprece-
dented restrictions have been implemented to control
the viral spread, including a complete lockdown of quar-
antine isolation in certain countries including Italy [1].
Concerns about the severe restrictions in mobility and
the subsequent sedentary lifestyle have been raised when
dealing with chronic neurological conditions, such as
Parkinson’s disease (PD) [2–5]. Falls are more common
(up to 40–70% per year) in advanced PD and their fre-
quency and severity increase with physical inactivity [6].
Overall, people with PD are twice more likely to experi-
ence falls than healthy elderly population [7]. Sedentary
time was significantly related to several aspects of quality
of life, including perceived deficits in mobility, cognitive
processing (e.g., memory, concentration), and communi-
cation (e.g., difficulty with speech) [8]. Moreover, it is
well-known that social deprivation affects cognition,
mood and quality of life [9, 10].
Since, physical exercise programs are essential compo-
nents in the management of motor and non-motor
symptoms in PD patients [11–13], the main objective of
this pre-post interventional study was to explore the
effects of COVID-19 related social and physical restric-
tions on this population.
Methods
Participants and ethics statement
Twelve PD participants from our Movement Disorders
and Parkinson Unit of the University Hospital of Padua
(Italy) were tested before and after the 2-months lock-
down period in Italy.
All participants had at screening (max 1 week before
the baseline visit): (i) diagnosis of idiopathic PD [14]; (ii)
Hoehn and Yahr (H&Y) score range 2-3 in the “OFF”
state [15]; (iii) Mini Mental State Examination (MMSE)
[16], score > 24; and (iv) stable pharmacological treat-
ment for the last 3 months. We excluded participants
who: (i) changed pharmacological treatment between
baseline and follow-up visits (i.e., during the 8 weeks of
lockdown); (ii) were demented based on MMSE score
and iADL and ADL or unable to understand and sign
the consent form; (iii) had deep brain stimulation and
infusion therapies; (iv) suffered from diabetes; (v)
reported pathologies of the musculoskeletal system; (vi)
had history of brain stroke, myocardial infarction or suf-
fered from uncontrolled hypertension; (vii) reported
urinary incontinence considering that the rehabilitation
program was planned in thermal water; and (viii) re-
ported relevant brain comorbidities or cerebrovascular
disease, as assessed with clinical T1w3D and FLAIR MRI
protocol. All patients were part of a larger cohort that
previously underwent thermal water rehabilitation. The
whole group underwent an extensive evaluation asses-
sing clinical, motor and cognitive aspects, which was ad-
ministered two weeks prior (pre-isolation: before March
11, 2020) and following the lockdown in Italy (post-iso-
lation: after May 4, 2020). The two evaluation sessions
were carried out at the same day time during patients
ON phase (see Fig. 1).
In order to be sure that participants had no close con-
tact with potential COVID-positive people or became
COVID-positive themselves between the two evaluation
sessions, a triage questionnaire was administered both
by telephone and in person at post-isolation visit.
Namely it was checked whether i) their body
temperature was lower than 37.5 °C, ii) they experienced
COVID-19 symptoms; iii) their family members or close
contacts (less than 1 meter in the same room for at least
15 min without protective equipment) confirmed or sus-
pected to have contracted COVID-19 in the 20 days
prior the evaluation; iv) they have ever been tested for
COVID-19, especially in the 20 days prior the evalu-
ation; and eventually if v) they have ever been positive to
COVID-19 tests. None of the patients included in this
study had history of positive COVID-19 or had contact
with positive people.
Participants were evaluated in the context of a project
that aimed to study the effect of rehabilitation in thermal
water on people with PD. This rehabilitation program
was interrupted due to the COVID-19 lockdown, but all
clinical assessments at baseline were successfully per-
formed the 2-weeks before lockdown. Participants were
evaluated by the multidisciplinary team in our clinic, which
includes a nurse case manager, neurologists, psychologists,
physiotherapists and bioengineers working in collaboration
with the rehabilitation unit and a study coordinator. Our
approach to patients’ management includes education and
training according to current recommendations [17, 18].
Assistance via phone calls and emails to those patients
who asked for it was granted during the lockdown period
and included training about low-intensity physical exer-
cises aimed to relieve immobility-associated pain (i.e.,
stretching exercises for neck, trunk and lower limbs) and
drugs administration. Although being of help, it is worth
noting that this intervention is far from the concept of de-
livering a proper telemedicine where patients can actively
interact with clinicians.
The study was carried out according to the Declar-
ation of Helsinki and ethical approval to data collection
was granted by the local review board. Participants read
and signed an informed written consent form before
participating to the study.
Clinical and motor assessment
Clinical description (age at disease onset, disease
duration, age, gender), and motor aspects (Unified
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Parkinson’s Disease Rating Scale part III (MDS-UPDRS
III) [19] and Hoehn and Yahr (H&Y) Scale [15]) were
collected by a neurologist experienced in the field of
movement disorders. Levodopa (LEDD) and dopamine
agonist equivalent daily (DAED) doses were calculated
[20], as well as the presence of ongoing anticholinergic
treatments.
A physical therapist specialized in movement disorders
collected the participants’ body mass and height to cal-
culate the participants’ body mass index (BMI, kg/m2)
and carried out the motor evaluation. The Mini-Balance
Evaluation Systems Test (Mini-BESTest), a shortened
version of the Balance Evaluation Systems Test (BEST-
est), was employed as clinical tool to measure balance
and predict the risk of falls [21]. The Mini-BESTest con-
sists of 14 items (scored from zero to two) organized in
four sections: anticipatory postural adjustments (APAs),
reactive postural control (RPC), sensory orientation (SO)
and dynamic gait (DG). The latter includes the Timed
Up and Go (TUG) and the Timed Up and Go with Dual
Task (TUG-DT). The TUG with and without dual task
is used to determine the effects of cognitive load on gait
performance. In the first three sections of the test, the
maximum score is six and for the latter is 10, with a
maximum total score of 28 points describing perfect
motor conditions, as described by [21]. The Mini-
BESTest is a significant predictor of falls and detector of
balance impairment in PD [22, 23], with one being ad-
dressed as potential faller when the total score is ≤ 17.5/
28 points [24].
Six Minute Walk Test (6MWT) was used to assess
participants’ aerobic capacity and endurance. The dis-
tance covered over a time of six minutes is recorded as
the outcome on which to contrast changes in perform-
ance and capacity. The test was carried out in an
obstacle-free corridor with a length of 30 meters [25].
The New Freezing of Gait Questionnaire (NFOG-Q) is
a self-reportable questionnaire consisting of nine items
that measure presence, severity and relevant impact of
freezing of gait (FOG) in individuals’ daily life [26]. The
higher the score, the larger the impact of FOG in indi-
viduals’ daily life.
Cognitive and functional assessment
A clinical semi-structured interview was carried out by
two experienced neuropsychologists performing the
cognitive-behavioral evaluation. The Montreal Cognitive
Assessment scale (MoCA) was administered to evaluate
global cognitive status as it has been shown that MoCA
is a sensitive and clinically useful cognitive screening in-
strument in parkinsonisms [27–30]; The MoCA good sen-
sitivity is likely to be due to the lack of ceiling effect, since
it explores attention-executive function whose perform-
ance has been previously associated with nigrostriatal
Fig. 1 Pre- and post-isolation evaluation protocol
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alterations [31, 32] and/or brain dopamine level [33]. The
MoCA is an 8-sections and 30-points scale with short
time of administration assessing visuospatial and executive
functions, naming ability, memory, attention, language,
abstraction, recall and orientation [34]. In order to avoid
learning effect between evaluations, alternative MoCA
versions were adopted at baseline and post-evaluation visit
[35]. Further, as one of the common characteristic of cog-
nitive impairment is the functional decline in instrumental
activities of daily functioning and subjective cognitive
complaints, we investigated their presence by using the
Parkinson’s disease cognitive functional rating scale (PD-
CFRS) [36]. Its performance allows to avoid motor biases
in capturing the functional impact of cognitive impair-
ment in Parkinson's disease and thus to adequately detain
the clinical significance of cognitive change. A score below
three is associated with normal cognition, a score above or
equal to three is associated with mild cognitive impair-
ment and a score above or equal to six to dementia. More-
over, we also administered the Activities of Daily Living
(ADL) [37] and the Instrumental Activities of Daily Living
(IADL) [38] questionnaires to further explore other as-
pects of daily life (such as occupational and personal care).
The ADL score range from 0 to six and the total score
below six is supportive of dementia. The IADL score
range from 0 to 8 (from female) and 0 to 6 (from male)
with 8/6 score means preserved functionality. Quality of
life was evaluate administering the Parkinson’s disease
Quality of Life Questionnaire (PDQ-39), which is a 39-
items questionnaire specific for PD, aiming to self-
evaluate the impact of the disease in individuals’ quality of
life in the following domains: (i) mobility, correlated with
physical function (10 items); (ii) activities of daily living,
associated with limitations due to physical problems (six
items); (iii) emotional well-being, associated with mental
health (six items); (iv) stigma (4 items); (v) social support,
(3 items); (vi) cognition (four items); (vii) communication
(four items); and (viii) bodily discomfort, associated with
pain (three items) [39]. Each question is expected to be
scored from zero (never) to five (always). The higher the
PDQ-39 total score, the larger the impact of PD in indi-
viduals’ daily life. To ensure consistency of the results, the
same neuropsychologist administered questionnaires and
tests to each participant pre- and post-isolation.
Statistical analysis
Statistics were calculated using IBM SPSS Statistics
(version 19.0, SPSS Inc., Chicago, Illinois).
For each variable, Minimal Detectable Change (MDC)
derived from literature was considered to evaluate the
noticeable change in ability [40]: Mini-BESTest (MDC=
4.1 [41]); MDS-UPDRS part III (MDC=4.63 [42]),
6MWD (MDC=82 m [43]), NFOG-Q (MDC=3 [44]),
BMI (MDC=2 kg/m2 [45]), MoCA (MDC=3 [46]).
The normality of scores distributions was assessed
using the Shapiro-Wilk test. Pre-post lockdown effects
on continuous variable were assessed with paired Two-
tailed Student’s t-tests and on categorical variables with
McNemar test. For those variables that do not satisfy
normality distribution, Median, 25-75-percentile values
and the paired Wilcoxon signed-rank test were consid-
ered. Effect size power analysis was calculated using
Cohen’s dZ measure correcting for small sample size and
between-repetitions Pearson correlation [47]. Achieved
power was calculated using G*power 3.1.9.4 tool [48].
An achieved power 0.8 and alpha =0.2 were considered
significant for the power analysis. Significance was set at
p < 0.05 (two-tailed). In order to test the dependency of
pre-post effect from baseline motor status, a GLM
ANCOVA was run between variables’ delta change and
baseline MDS-UPDRS part III score.
Results
Participants’ sociodemographic and clinical characteris-
tics at the screening visit (pre-isolation period) are
shown in Table 1. Throughout the whole quarantine
period, there were no changes in drug therapy. Four in-
dividuals reported more than one fall during this period,
whereas only one reported falls prior the baseline visit.
Six participants reported drug-controlled hypertension,
and two of them had suffered from ischemic heart dis-
ease. None of our participants was on acetylcholinester-
ase inhibitors (AChE).
Impact of lockdown on clinical and motor performance
Ten participants asked for telephone assistance during
the lockdown period as they reported pain associated
Table 1 Social and demographical patients’ characteristic at the
screening visit. Data are given as median values with 1st and 3rd
quartiles (25- and 75-percentile, respectively Q1 and Q3), or as
frequencies (N, %)
Whole PD sample (n=12)
Median (Q1; Q3) /Frequency
Age (years) 69.5 (67.0; 73.8)
Gender (male) 8 (67%)
Education (years) 10.5 (8.0; 13.8)
Age at disease onset (years) 58.0 (54.0; 64.25)
Disease duration (years) 10.0 (8.0; 13.3)
LEDD (mg/die) 745.0 (590.0; 1298.5)
DAED (mg/die) 105.0 (45.5; 210.0)
H&Y 2.5 (2; 3)
MMSE (corrected score) 29.0 (29.0; 29.3)
Live alone 2 (16%)
Freezing of Gait 7/5 (59%)
Tremor 9/3 (75%)
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with poor daily mobility. The other two participants
reported a good autonomy in self delivering stretching
exercises that were performed on a daily basis.
Table 2 shows the results obtained for each variable
pre- and post-isolation, as well as the relevant statistical
results. A significant increment in the BMI was detected
(p = 0.031, dz = 0.703). Differences in MDS-UPDRS part
III total score were not significant (p = 0.092). Six
subjects showed an increasing of the MDS-UPDRS part
III equal or superior to +4.63 points. Four of them
remained stable and the other two showed a variation of
-3.25 points. The Mini-BESTest total score was signifi-
cantly reduced (p = 0.005, dz = 0.994). Namely, an in-
creased number of participants (six at the post-isolation
vs. one at pre-isolation visit) obtained less than 17.5
points, the PD cutoff for potential fallers at the Mini-
BESTest total score. In particular, four participants dis-
played a decline in the APAs sub-score; four participants
worsened in the RPC, whereas similar values were
observed in the SO and DG sub-scores in pre- and post-
isolation visits. Post-hoc power analysis indicated that
the power to detect obtained effects at the 0.2 level was
0.861 for the effect of lockdown on Mini-BESTest
performance.
Additionally, statistical analysis revealed no significant
differences in the 6MWT (p=0.799) and the NFOG-Q
questionnaire (p=0.313) between pre- and post-isolation
evaluations.
Impact of lockdown restrictions on cognitive performance
and quality of life
No differences were found in the ADL and IADL
questionnaires. No significant effect was found on global
cognitive performance as assessed with MoCA scale
(p=0.392), nor in the PD-CFRS total score (p=0.123).
Qualitative analysis of the PD-CFRS sub-items showed
that four patients reported language (anomia/comprehen-
sion) problems and inability to remember drug intakes.
Overall, PDQ-39 score did not change (p=0.472) but
qualitative analysis shows a worsening in the "emotional
well-being" domain in two subjects while 10 was in a simi-
lar condition.
Discussion
To the best of our knowledge, this is the first study
assessing the consequences of the COVID-19 related re-
strictions on both motor and non-motor symptoms of
people with PD who had never contracted COVID-19.
Considering that our subjects had been assessed just be-
fore the implementation of strict lockdown, we had the
unique opportunity to test the impact of isolation with-
out any treatment change and through a systematic and
complete evaluation.
Our findings showed that no significant worsening in
clinical measures and quality of life were detected for
this cohort of PD patients in the mild and moderate
stages of the disease. These findings should be inter-
preted considering that PD participants were followed
regularly at our clinic and attended several educational
activities at our local Parkinson lay association. We sug-
gest that these results further point to the importance of
multidisciplinary care interventions for PD patients to
hand and learn self-management strategies [17, 18].
The only worsening item we detected was the Mini-
BESTest total score. This finding could indicate that, if
the lockdown period had continued, we could have
Table 2 Comparison of results of each variable pre- and post-isolation period. Data are given as median values with 1st and 3rd





Cohen dz Achieved Power
c p-valuea,b
BMI (kg/m2) 26.5 (23.0; 29.6) 27.4 (23.2; 29.6) 0.703 0.841 0.031bd
MDS-UPDRS Part III 14.5 (11.8; 21.3) 19 (12.8; 31.0) 0.513 0.651 0.092a
Mini-BESTest 23 (21.0; 25.5) 19 (16.3; 21.0) 0.994 0.974 0.005bd
6MWT (m) 565.5 (370.8; 660.6) 510.0 (405.0; 665.0) 0.027 0.201 0.799b
NFOG-Q 6.0 (0.0; 13.8) 8.5 (0.0; 15.5) 0.353 0.454 0.313a
MoCA (corrected score) 24.2 (21.7; 26.0) 24.5 (23.3; 26.0) 0.257 0.345 0.392b
PD-CFRS 0.5 (0.0; 1.0) 1.0 (0.8; 1.0) 0.677 0.821 0.123a
IADL 5 (5.0; 6.3) 5 (5.0; 6.3)
ADL 6.0 (6.0; 6.0) 6.0 (6.0; 6.0)
PDQ-39 30.5 (17.0; 45.3) 32.5 (20.0; 44.3) 0.215 0.304 0.472b
Note. aWilcoxon signed-rank test or bt-test for continuous variable and McNemar test for discrete variable. MDS-UPDRS Part III = MDS-Unified Parkinson Disease
Rating Scale - part III; Mini-BESTest = Mini-Balance Evaluation Systems Test. 6MWT = Six-minute walk test; NFOG-Q = New Freezing of Gait Questionnaire. MoCA =
Montreal Cognitive Assessment scale; PD-CFRS = Parkinson’s disease cognitive functional rating scale; ADL = Activities of Daily Living questionnaire; IADL =
Instrumental Activities of Daily Living questionnaire; BMI = Body Mass Index; PDQ-39 = Parkinson’s disease Quality of Life Questionnaire. cPost-hoc power analysis.
Achieved power was calculated based on Cohen’s dz and an α error probability of 0.2
dSignificant isolation period effect (pre vs. post-isolation evaluation)
Luis-Martínez et al. BMC Neurology          (2021) 21:332 Page 5 of 8
possibly observed a clinically significant deterioration in
balance performance of these individuals. The Mini-
BESTest has proven to be a significant predictor of falls
and detector of balance problems in PD [22, 23], and
our result indicate that drastic mobility restrictions have
a negative impact on balance. Indeed, the clinical cutoff
to consider an individual as a faller via the Mini-
BESTest is a total score equal to 17.5/28 points [24].
Contrarily to what observed before the lockdown (only 1
participant with Mini-BESTest total score < 17.5, who
reported falls prior the baseline visit), six out of 12 par-
ticipants did not pass such a threshold at the post-
isolation visit, with four of them reporting falls during
the 2-months lockdown. Four of them showed a decline
in the APAs Mini-BESTest sub-items. Anticipatory Pos-
tural Adjustments (APA) are the necessary weight shift
mechanism that occur prior to an internal or external
postural challenge, such as step initiation and postural
transfers (e.g. sit-to-stand task). Thus, this neural pro-
cessing is required to achieve good control of center of
mass transition in order to avoid a loss of balance and a
subsequent fall [49, 50]. Remarkably, the rest of partici-
pants did not show clinical changes.
MDS-UPDRS motor examination total score
highlighted only a modest median worsening. However,
considering the minimal threshold of +4.63 points for
detecting clinically meaningful worsening changes in the
score of the MDS-UPDRS part III, this variation was
clinically relevant for six of these participants [42]. The
fact that only half of these participants showed a clinic-
ally negative effect, and that the 6MWT did not differ,
could be explained with these participants and their
caregivers having received an extensive training and edu-
cation strategies for managing PD symptoms over the
years at our clinic. Moreover, our multidisciplinary inter-
ventions were not substantially interrupted during this
period thanks to remote-technology solutions. We suc-
ceeded in driving technology-based assistance for any re-
quirement and promoting physical activity solutions in
any case. This is consistent with the results of a recent
survey for an Italian PD patients’ cohort about how the
lockdown impacted on physical activity. This resulted in
successful self-management patient’s strategies to con-
tinue physical activity at home. Moreover, education and
awareness on the importance of physical activity were
identified as main factors for the preservation of health
in PD patients [51]. The body mass index experienced
an increase, suggesting that this profound change in
daily routine and regular physical activity had resulted in
increased body weight, although this may not be specific
of PD.
Finally, it should be noticed that baseline clinical, cog-
nitive and functional status was relatively mild for this
cohort and PDQ-39 score confirmed that patients were
stable, and symptoms were well controlled with pharma-
cological treatment. Emotional wellbeing was the only
domain showing a trend for worsening most likely due
to prolonged social isolation [52]. Overall, it should be
considered the relative shortness of the isolation period
(8 weeks) together with the good baseline values of these
patients and the uninterrupted remote assistance have
possibly softened negative impacts of strict lockdown.
Limitations of the study
The present study has two main drawbacks. The unpre-
cedented conditions of this pandemic gave us the unique
opportunity to explore the impact of a full lockdown on
motor and non-motor symptoms in PD patients, but
also limited the possibility to both perform an a-priori
sample size calculation for our population, and to recruit
an aged-matched control group. It is also worth noting
that seven of the 12 participants completed an intensive
motor rehabilitation program before the lockdown
period, thus the overall outcome of the results might be
affected. All the participants were yet at similar stage of
the disease at the baseline. Another limitation worth
mentioning is the unavoidable lack of control on how
each participant managed to achieve a good quality of
either the suggested or self-administered low-intensity
physical exercises during the lockdown period.
Conclusion
Our study provides the unique opportunity to test, with
the same clinical measurements, in real life and in un-
precedented mobility restrictions, the effects of isolation
in PD. Even if the overall changes were modest, we ob-
served an increased risk of falls in selected individuals
which is nonetheless potentially relevant. The potentially
negative effects of lockdown may have been softened by
previous participation of these patients to educational
activities and continued availability of our multidisciplin-
ary team.
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